Live Breaking News & Updates on Frederic triebel

Stay informed with the latest breaking news from Frederic triebel on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Frederic triebel and stay connected to the pulse of your community

Immutep Quarterly Activities Report Q2 FY24

Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer patients expressing PD-L1...

France , Sydney , New-south-wales , Australia , Germany , Poland , Monash , South-australia , Polish , German , French , Australian

Immutep to Participate in November Investor Events

Immutep to Participate in November Investor Events
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Australia , Sydney , New-south-wales , Australian , Chris-basta , Wade-iams , Marc-voigt , Christian-mueller , Frederic-triebel , Nasdaq , Immutep-limited , Corporate-communications

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49%, and ≥50%), differen

Badalona , Comunidad-autonoma-de-cataluna , Spain , Australia , United-states , Sydney , New-south-wales , Australian , Frederic-triebel , Christian-mueller , Florian-vogl , Marc-voigt

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Media ReleaseNew updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Satur...

Australia , Sydney , New-south-wales , United-states , Frankfurt , Brandenburg , Germany , Australian , Enric-carcereny , Chris-basta , Florian-vogl , Katarzyna-kozak

Immutep (IMMP) Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

Immutep (IMMP) Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Marc-voigt , Frederic-triebel , I-sant-pau , Margarita-majem , Department-of-medical-oncology , European-lung-cancer-congress , Nasdaq , Immutep-limited , Wall-street , Mini-oral , Lung-cancer-congress , Medical-oncology

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care... | March 31, 2023

Australia , Sydney , New-south-wales , United-states , Australian , Frederic-triebel , Marc-voigt , Margarita-majem , Chris-basta , Sant-pau , Drug-administration , Department-of-medical-oncology

Immutep trial enrolls target for NSCLC: INSIGHT-003

Immutep trial enrolls target for NSCLC: INSIGHT-003
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Australia , Australian , Frederic-triebel ,

Immutep (IMMP) Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC

Immutep (IMMP) Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Australia , United-states , Canada , Australian , American , Immutepceo-marc-voigt , Wadet-iams , Frederic-triebel , Immutep-limited , American-society-of-clinical-oncology , Society-of-immunotherapy-cancer , Drug-administration

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Australia , United-states , Canada , Sydney , New-south-wales , Australian , American , Immutepceo-marc-voigt , Wadet-iams , Frederic-triebel , Tim-mccarthy , Immutep-limited

Immutep (IMMP) Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC

Immutep (IMMP) Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Australia , United-states , Canada , Australian , American , Immutepceo-marc-voigt , Wadet-iams , Frederic-triebel , Immutep-limited , American-society-of-clinical-oncology , Society-of-immunotherapy-cancer , Drug-administration